Meeting: 2017 ASCO Annual Meeting Track: Oral Abstract Session Breast Cancer – Metastatic Abstract number: LBA4 Citation: J Clin Oncol 35, 2017 (suppl; abstr LBA4) Authors: Mark E. Robson, Seock-Ah Im, Elżbieta Senkus, et al. Background: Olaparib is an oral PARP inhibitor with anti-tumor activity in HER2-negative mBC with a gBRCAm...
Pro zobrazení tohoto obsahu je třeba být přihlášen.